← Back to Search

Other

RP-6306 Combination Therapy for Cancer

Phase 2
Recruiting
Research Sponsored by Canadian Cancer Trials Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial is testing RP-6306, a new drug, to see if it can help treat cancer when used with standard treatments. It focuses on patients with specific biomarkers to see if they respond better. The drug works by blocking a protein that helps cancer cells grow.

Who is the study for?
Adults with advanced cancers like endometrial, NSCLC, ovarian carcinosarcoma, TNBC, PDAC, colorectal cancer or HER-2+ gastroesophageal cancer. They must have tried some treatments already (like platinum-based chemotherapy), be in good physical condition and expected to live at least 3 months. Specific genetic markers are required for some cohorts. Pregnant women and those with certain health conditions or previous hypersensitivity to study drugs can't join.
What is being tested?
The trial is testing RP-6306's safety and effectiveness against various advanced cancers when combined with standard treatments such as Gemcitabine or FOLFIRI Protocol. It also examines if patients' biomarkers affect their response to the treatment compared to usual cancer care approaches.
What are the potential side effects?
Potential side effects of RP-6306 and other drugs used in this trial may include reactions related to drug infusion, impact on blood cells leading to increased infection risk, fatigue, digestive issues due to oral medication absorption problems, and possibly organ inflammation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

3Treatment groups
Active Control
Group I: RP-6306 + TrastuzumabActive Control2 Interventions
Group II: RP-6306 + GemcitabineActive Control2 Interventions
Group III: RP-6306 + FOLFIRIActive Control2 Interventions

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Cancer treatments work through various mechanisms to target and destroy cancer cells. Chemotherapy uses drugs to kill rapidly dividing cells, affecting both cancerous and some healthy cells. Targeted therapies, like those being studied in trials such as RP-6306, focus on specific molecules or pathways crucial for cancer cell growth and survival, thereby minimizing damage to normal cells. Immunotherapy boosts the body's immune system to recognize and attack cancer cells. Radiation therapy uses high-energy particles to damage the DNA of cancer cells, leading to cell death. Understanding these mechanisms helps patients and doctors choose the most effective treatment plan, manage side effects, and improve overall outcomes.
Emerging treatments in lung cancer - targeting the RLIP76 molecular transporter.Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology.Overcoming therapeutic resistance in malignant gliomas: current practices and future directions.

Find a Location

Who is running the clinical trial?

Canadian Cancer Trials GroupLead Sponsor
129 Previous Clinical Trials
69,154 Total Patients Enrolled
Repare TherapeuticsIndustry Sponsor
9 Previous Clinical Trials
1,240 Total Patients Enrolled
Yvette DrewStudy ChairBCCA-Vancouver Cancer Centre, Vancouver BC Canada

Media Library

RP-6306 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05605509 — Phase 2
Cancer Research Study Groups: RP-6306 + Trastuzumab, RP-6306 + Gemcitabine, RP-6306 + FOLFIRI
Cancer Clinical Trial 2023: RP-6306 Highlights & Side Effects. Trial Name: NCT05605509 — Phase 2
RP-6306 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05605509 — Phase 2
~4 spots leftby Dec 2024